CIK 0001357874 · Non-accelerated filer<br>Smaller reporting company
PRECISION BIOSCIENCES INC
Sign in to watch- Ticker
- DTIL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- May 21
- Incorporated
- DE
- Entity type
- operating
- Phone
- 919-314-5512
- Business address
- 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM, NC, 27701
- Open-market buys, last 90 days
- $29,501
- in 3 filings
- Open-market sales, last 90 days
- $27,505
- in 1 filing, $28K under 10b5-1 plans
Net +$1,996. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-20 | SMITH J. JEFFERSON Chief Research Officer | Option exercise · Restricted Stock Units 10b5-1 | −2,500 | 0 | ||
| 2026-01-20 | SMITH J. JEFFERSON Chief Research Officer | Option exercise · Restricted Stock Units 10b5-1 | −10,447 | 10,447 | ||
| 2026-01-20 | SMITH J. JEFFERSON Chief Research Officer | Option exercise · Restricted Stock Units 10b5-1 | −16,219 | 16,219 | ||
| 2025-12-16 | Germano Geno J Director | Purchase | +3,000 | $4.72 | $14K | 23,883 |
| 2025-12-16 | Frankel Stanley Director | Purchase | +2,700 | $4.70 | $13K | 19,478 |
| 2025-12-15 | Brown Melinda Director | Purchase | +1,381 | $4.97 | $7K | 23,346 |
| 2025-11-03 | Kelly John Alexander Chief Financial Officer | Sale 10b5-1 | −1,303 | $6.49 | $8K | 77,298 |
| 2025-11-03 | Scimeca Dario General Counsel and Secretary | Sale 10b5-1 | −665 | $6.49 | $4K | 28,258 |
| 2025-11-03 | Amoroso Michael President and CEO | Sale 10b5-1 | −3,409 | $6.49 | $22K | 115,575 |
| 2025-11-03 | Amoroso Michael President and CEO | Option exercise · Restricted Stock Units 10b5-1 | −9,444 | 0 | ||
| 2025-11-02 | Kelly John Alexander Chief Financial Officer | Option exercise 10b5-1 | +3,605 | 78,601 | ||
| 2025-11-02 | Kelly John Alexander Chief Financial Officer | Option exercise · Restricted Stock Units 10b5-1 | −3,605 | 0 | ||
| 2025-11-02 | Scimeca Dario General Counsel and Secretary | Option exercise 10b5-1 | +1,835 | 28,923 | ||
| 2025-11-02 | Scimeca Dario General Counsel and Secretary | Option exercise · Restricted Stock Units 10b5-1 | −1,835 | 0 | ||
| 2025-11-02 | Amoroso Michael President and CEO | Option exercise 10b5-1 | +9,444 | 118,984 | ||
| 2025-09-26 | Frankel Stanley Director | Purchase | +2,700 | $4.97 | $13K | 16,778 |
| 2025-09-22 | Brown Melinda Director | Purchase | +1,400 | $4.89 | $7K | 21,965 |
| 2025-07-03 | Kelly John Alexander Chief Financial Officer | Sale 10b5-1 | −14,827 | $4.26 | $63K | 73,485 |
| 2025-06-25 | Brown Melinda Director | Purchase | +1,682 | $4.14 | $7K | 20,565 |
| 2025-06-25 | Buehler Kevin Director | Purchase | +5,076 | $4.16 | $21K | 28,137 |
Page 4 of 11 · 210 trades